Titre :

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study

Auteur(s) :

Assié, Jean-Baptiste [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Crépin, Florian [Auteur]
Grolleau, Emmanuel [Auteur]
Université de Poitiers = University of Poitiers [UP]

Laboratoire d'informatique et d'automatique pour les systèmes [LIAS [Poitiers]]
Canellas, Anthony [Auteur]
Geier, Margaux [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Grébert-Manuardi, Aude [Auteur]
Akkache, Nabila [Auteur]
Centre Hospitalier d'Aix en Provence [Aix-en-Provence] [CHIAP ]
Renault, Aldo [Auteur]
Intergroupe Francophone de Cancérologie Thoracique [Paris] [IFCT]
Hauss, Pierre-Alexandre [Auteur]
Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen]
Sabatini, Marielle [Auteur]
Bonnefoy, Valentine [Auteur]
Cortot, Alexis [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Site de Recherche Intégrée en Cancérologie [SIRIC-ONCOLille]
Wislez, Marie [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]
Cancer Research and Personalized Medicine - CARPEM [Paris] [SIRIC CARPEM]
Gauvain, Clément [Auteur]
Chouaïd, Christos [Auteur]
IMRB - CEPIA/"Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health" [Créteil] [U955 Inserm - UPEC]
Centre Hospitalier Intercommunal de Créteil [CHIC]
SCHERPEREEL, Arnaud [Auteur]
Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 [OncoThAI]
Monnet, Isabelle [Auteur]
Matériaux, Défauts et IRradiations [MADIR]
Centre de recherche sur les Ions, les MAtériaux et la Photonique [CIMAP - UMR 6252]

Titre de la revue :

Cancers

Pagination :

1498

Éditeur :

MDPI

Date de publication :

2022-03

ISSN :

2072-6694

Mot(s)-clé(s) en anglais :

malignant pleural mesothelioma
immune-checkpoint inhibitors
real-world study
nivolumab
second-line regimen

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Cancer

Résumé en anglais : [en]

Backgrounds: Malignant pleural mesothelioma (MPM) is a cancer with poor prognosis. Second-line and onward therapy has many options, including immune-checkpoint inhibitors with demonstrated efficacy: 10–25% objective response ...
Lire la suite >Backgrounds: Malignant pleural mesothelioma (MPM) is a cancer with poor prognosis. Second-line and onward therapy has many options, including immune-checkpoint inhibitors with demonstrated efficacy: 10–25% objective response rate (ORR) and 40–70% disease-control rate (DCR) in clinical trials on selected patients. This study evaluated real-life 2L+ nivolumab efficacy in MPM patients and looked for factors predictive of response. Methods: This retrospective study included (September 2017–July 2021) all MPM patients managed in 11 French centers. Results: The 109 enrolled patients’ characteristics were: median age: 69 years; 67.9% men; 82.6% epithelioid subtype. Strictly, second-line nivolumab was given to 51.4%. Median PFS and OS were 3.8 (3.2–5.9) and 12.8 (9.2–16.4) months. ORR was 17/109 (15.6%); 34/109 patients had a stabilized disease (DCR 46.8%). Univariable analysis identified several parameters as significantly (p < 0.05) prognostic of OS [HR (95% CI)]: biphasic subtype: 3.3 (1.52–7.0), intermediate Lung Immune Prognostic Index score: 0.46 (0.22–0.99), progression on the line preceding nivolumab: 2.1 (1.11–3.9) and age > 70 years: 2.5 (1.5–4.0). Multivariable analyses retained only biphasic subtype: 3.57 (1.08–11.8) and albumin < 25 g/L: 10.28 (1.5–70.7) as significant and independent predictors. Conclusions: Second-line and onward nivolumab is effective against MPM in real life but with less effectiveness in >70 years. Ancillary studies are needed to identify the predictive factors.Lire moins >

Langue :

Anglais

Collections :

• Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189

Source :

Harvested from HAL

Date de dépôt :

2023-06-29T02:56:23Z